Levofloxacin, a second-generation fluoroquinolone

Pharmacotherapy

Volumn 18, Issue 5, 1998, Pages 915-935

  North, Donald S ^a   Fish, Douglas N ^b   Redington, J Jay ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTACID AGENT; CATION; CEFACLOR; CEFTRIAXONE; CEFUROXIME AXETIL; CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOSPORIN; DIVALENT CATION; DNA TOPOISOMERASE (ATP HYDROLYSING); LEVOFLOXACIN; LOMEFLOXACIN; OFLOXACIN; PENICILLIN G; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE; ZIDOVUDINE;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNICABLE DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; GASTROINTESTINAL TOXICITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PENICILLIN RESISTANCE; POSTANTIBIOTIC EFFECT; PYELONEPHRITIS; REVIEW; SINUSITIS; SKIN INFECTION; URINARY TRACT INFECTION;

ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; BIOLOGICAL AVAILABILITY; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN;

EID: 0031656171     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (158)

1. Ortho-McNeil Pharmaceuticals. Levaquin (levofloxacin) package insert. Raritan, NJ;December 1996.
2. Hayakawa I, Atarashi S, Yokohama S, et al. Synthesis and antimicrobial activities of optically active ofloxacin. Antimicrob Agents Chemother 1986;29:163-4.
3. Fu KP, Lafredo SC, Foleno B, et al. In vitro and in vivo antibacterial activities of levofloxacin, an optically active ofloxacin. Antimicrob Agents Chemother 1992;36:860-6.
4. RW Johnson Pharmaceutical Research Institute. Data on file. Raritan, NJ;1997.
5. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989;2(4):378-424.
6. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32(2):101-19.
7. Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47(4):677-700.
8. Imamura M, Shibamura S, Hayakawa I, et al. Inhibition of DNA gyrase by optically active ofloxacin. Antimicrob Agents Chemother 1987;31:325-7.
9. Fu KP, Grace ME, McCloud SJ, et al. Discrepancy between the antibacterial activities and the inhibitory effects of Micrococcus luteus DNA gyrase of 13 quinolones. Chemotherapy 1986;29:494-8.
10. Lewin DS, Morrissey I, Smith JT. The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment. Eur J Clin Microbiol Infect Dis 1991;10:240-8.
11. Une T, Fujimoto T, Sato K, Osada Y. In vitro activity of an optically active ofloxacin. Antimicrob Agents Chemother 1988;32(9):1336-40.
12. Tanaka M, Otsuki M, Una T, Nishino T. In-vitro and in-vivo activity of DR-3355, an optically active isomer of ofloxacin. J Antimicrob Chemother 1990;26:659-66.
13. Morrissey I, Smith JT. The effect of inoculum size on 4-quinolone uptake by Escherichia coli KL-16. J Pharm Pharmacol 1993;45(suppl): 1106-8.
14. Neu HC, Chin N-X. In vitro activity of S-ofloxacin. Antimicrob Agents Chemother 1989;33:1105-7.
15. Eliopoulos GM, Wennersten CB, Moellering RC Jr. Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria. Diagn Microbiol Infect Dis 1996;25:35-41.
16. Felmingham D, Robbins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother 1997;39(suppl B):43-9.
17. Biedenbach DJ, Jones RN. The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagn Microbiol Infect Dis 1996;25:47-51.
18. Klugman KP, Capper T, Bryskier A. In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin. Antimicrob Agents Chemother 1996;40:2802-4.
19. Pankuch GA, Jacobs MR, Applebaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995;35:230-2.
20. Plouffe JF, and the Franklin County Pneumonia Study Group. Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1996;25:43-5.
21. Fuchs PC, Barry AL, Brown SD. Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, ofloxacin and levofloxacin. J Antimicrob Chemother 1997;39:671-2.
22. George J, Morrissey I. The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae. J Antimicrob Chemother 1997;39:719-23.
23. Hayden MK, Matushek MG, Trenholme GM. Comparison of the in vitro activity of levofloxacin and other antimicrobial agents against vancomycin-susceptible and vancomycin-resistant Enterococcus species. Diagn Microbiol Infect Dis 1995;22:349-52.
24. Edelstein PH, Edelstein MA, Lehr KH, Ren J. In-vitro activity of levofloxacin against clinical isolates of Legionella spp, its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother 1996;37:117-26.
25. Yew WW, Piddock JY, Li MSK, et al. In-vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 1994;34:343-51.
26. Skinner PS, Furney SK, Kleinert DA, Orme IM. Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:750-3.
27. Ji B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:1341-4.
28. Rastogi N, Goh KS, Bryskier A, Devallois A. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996;40:1610-16.
29. Rastogi N, Goh KS, Bryskier A, Devallois A. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob Agents Chemother 1996;40:2483-7.
30. Inagaki Y, Horiuchi S, Une T, Nakaya R. In vitro activity of DR-3355, an optically active isomer of ofloxacin against bacterial pathogens associated with traveller's diarrhoea. J Antimicrob Chemother 1989;24:547-9.
31. Cormican MG, Erwin ME, Marshall SA, Jones RN. Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis. Diagn Microbiol Infect Dis 1996;24:155-60.
32. Spangler SK, Visall MA, Jacobs MR, Applebaum PC. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem. Antimicrob Agents Chemother 1996;40:772-5.
33. Madinger NE, McGregor JA, McKinney PJ, et al. Comparative antibiotic susceptibilities of anaerobes associated with infections of the female reproductive tract. Clin Infect Dis 1993;16(suppl 4):S349-52.
34. Hammerschlag MR, Qumel KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1994;38:1402-3.
35. Morrissey I, Khatri N, Leighton H, et al. The interaction between the 4-quinolone S(-)-ofloxacin and other antibacterials against Streptococcus pneumoniae. J Pharm Pharmacol 1992;44(suppl):1057-9.
36. Smith CE, Foleno BE, Barrett JF, Frosco MB. Assessment of the synergistic interactions of levofloxacin and ampicillin against Enterococcus faecium by the checkerboard agar dilution and time-kill methods. Diagn Microbiol Infect Dis 1997;27:85-92.
37. Bajaksouzian S, Visalli MA, Jacobs MR, Appelbaum PC. Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against Acinetobacters as determined by checkerboard and time-kill studies. Antimicrob Agents Chemother 1997;41:1073-6.
38. Patel JA, Pachucki CT, Lentino JR. Synergy of levofloxacin (L-ofloxacin) and oxacillin against quinolone-resistant Staphylococcus aureus, measured by the time-kill method. Antimicrob Agents Chemother 1993;37:339-41.
39. Fu KP, Foleno B, Rosenthale ME. The postantibiotic suppressive effect of l-ofloxacin, an optically active isomer of ofloxacin. Diagn Microbiol Infect Dis 1992;15:375-8.
40. Tanaka M. Une T, Osada Y. Sub-inhibitory and postantibiotic effects of an optically active isomer of ofloxacin. Arzneimittelforschung 1989;39:750-4.
41. Wiedemann B, Heisig P. Mechanisms of quinolone resistance. Infection 1994;22(suppl 2):S73-9.
42. Piddock LJV. Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs 1995;49(suppl 2):29-35.
43. Cambau E, Sougakoff W, Besson M, Truffot-Pernot C, Grosset J, Jarlier V. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. J Infect Dis 1994;170:479-83.
44. Alangaden GJ, Manavathu EK, Vakulenko SB, Zvonok NM, Lerner SA. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 1995;39:1700-3.
45. Yoshida H, Nakamura M, Bogaki M, Nakamura S. Proportion of DNS gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990;34:1273-5.
46. Heisig P. High-level fluoroquinolone resistance in a Salmonella typhimurium isolate due to alterations in both gyrA and gyrB genes. J Antimicrob Chemother 1993;32:367-77.
47. Ouabdesselam S, Hooper DC, Tankovic J, Soussy CJ. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrob Agents Chemother 1995;39:1667-70.
48. Peng H, Marians KJ. Escherichia coli topoisomerase intravenous. Purification, characterization, subunit structure, and subunit interactions. J Biol Chem 1993;268:24481-90.
49. Hoshino K, Kitamura A, Morrissey I, et al. Comparison of inhibition of Escherichia coli topoisomerase intravenous by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother 1994;38:2623-7.
50. Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1995;39:1554-8.
51. Ferrero L, Cameron B, Manse B, et al. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase intravenous: a primary target of fluoroquinolones. Mol Microbiol 1994;13:641-53.
52. Korten V, Huang WM, Murray BE. Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis. Antimicrob Agents Chemother 1994;38:2091-4.
53. Chapman JS, Bertasso A, Georgopapadakou NH. Fleroxacin resistance in Escherichia coli. Antimicrob Agents Chemother 1989;33:239-42.
54. Cohen SP, Hooper DC, Wolfson JS, et al. Endogenous active efflux of norfloxacin in susceptible Escherichia coli. Antimicrob Agents Chemother 1988;32:1187-91.
55. Cohen SP, McMurry LM, Hooper DC, Wolfson JS, Levy SB. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction. Antimicrob Agents Chemother 1989;33:1318-25.
56. Bazile S, Moreau N, Bouzard D, Essiz M. Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones. Antimicrob Agents Chemother 1992;36:2622-7.
57. Tanaka M, Zhang YX, lshida H, Akasaka T, Sato K, Hayakawa I. Mechanisms of 4-quinolone resistance in quinolone-resistant and methicillin-resistant Staphylococcus aureus isolates from Japan and China. J Med Microbiol 1995;42:214-19.
58. Kaatz GW, Seo SM, Ruble CA. Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. J Infect Dis 1991;163:1080-6.
59. Kaatz GW, Seo SM. lnducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1995;39:2650-5.
60. Poole K, Krebes K, McNally K, et al. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol 1993;175:7363-72.
61. Li X-Z, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: resistance to tetracycline, chloramphenicol and norfloxacin. Antimicrob Agents Chemother 1994;38:1732-41.
62. Okazaki O, Kojima C, Hakusui H, et al. Enantioselective disposition of ofloxacin in humans. Antimicrob Agents Chemother 1991;35:2106-9.
63. Nakashima M, Uematsu T, Kanamaru M, et al. Phase I study of levofloxacin, (S)-(-)-ofloxacin. Jpn J Clin Pharmacol Ther 1992;23:515-20.
64. Sasaki J, Morishima T, Shiiki K, et al. Clinical study of levofloxacin in treatment of odontogenic infections. Chemotherapy 1992;40(suppl 3):379-91.
65. Goodwin SD, Gallis HA, Chow AT, Wong FA, Flor SC, Bartlett JA. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1994;38:799-804.
66. Holland ML, Chien S-C, Corrado ML, Flor SC, Rogge MC. The pharmacokinetic profile of levofloxacin following once-or twice-daily 500 mg oral administration of levofloxacin hemihydrate [abstr]. Presented at the 5th international symposium on new quinolones, Singapore, Malaysia, August 25-27, 1994.
67. Chien SC, Chow AT, Fowler CL, et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750 mg and 1 g doses of levofloxacin in healthy volunteers [abstr]. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996.
68. Holland ML, Chien S-C, Corrado ML, Flor SC, Rogge MC. The pharmacokinetic profile of intravenous levofloxacin following once-or twice-daily 500 mg administration [abstr]. Presented at the 5th international symposium on new quinolones, Singapore, Malaysia, August 25-27, 1994.
69. Chien S-C, Rogge MC, Gisclon LG, et.al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997;41(10):2256-60.
70. Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 1985;28:716-21.
71. Tanaka K-I, Iwamoto M, Maesaki S, et al. Basic and clinical studies on levofloxacin in the treatment of respiratory infections, Jpn J Antibiot 1992;45:548-55.
72. Lee L-J, Hafkin B, Lee I-D, Hoh J, Dix R. Effects of food and sucralfate on a single oral dose of 500 mg of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997;41(10):2196-2200.
73. Child J, Mortiboy D, Andrews JM, Chow AT, Wise R. Open-label crossover study to determine the pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother 1995;39:2749-51.
74. Ohi Y, Goto T, Kawahara K, Kawahara M, Kawabata T, Nagayama K. Penetration of fluoroquinolones into human spinal fluid. Chemotherapy 1992;40:469-73.
75. Tomii T, Fukuda M, Sasaki K. Penetration of l-ofloxacin (DR-3355) into the lacrimal fluid. Jpn J Clin Ophthalmol 1991;45:1607-10.
76. Nakamori Y, Tsuboi E, Narui K, Nakatani T, Nakata K, Sugi H. Sputum penetration of levofloxacin and its clinical efficacy in patients with chronic lower respiratory tract infections. Jpn J Antibiot 1992;45:539-47.
77. Baba S, Miyamoto N, Yanai O, et al. Study on the penetration of levofloxacin (DR-3355) into the otorhinolaryngeal tissues and discharges in patients. Chemotherapy 1992;40(suppl 3):326-33.
78. Inoue S, Misaki M, Matsumura K. Intraocular penetration of DR-3355. Atarashii Ganka [J Eye] 1992;9:487-90.
79. Nagai H, Yamasaki T, Masuda M, Goto Y, Tasiro T, Nasu M. Penetration of levofloxacin into bronchoalveolar lavage fluid. Drugs 1993;45(suppl 3):259.
80. Hukagawa H, Noga K. A study on the concentration of levofloxacin in the gallbladder tissue and bile of patients, Jpn J Antibiot 1992;45:253-7.
81. Ohnishi H, Tanimura H, Ichimaya G, et al. Excretion of levofloxacin into bile and gallbladder tissue. Drugs 1993;45(suppl 3):260-1.
82. Tanimura H, Ohnishi H, Okamura T, et al. Chemotherapy of biliary tract infections (XXXVII). Excretion into bile and gallbladder tissue levels of levofloxacin and its clinical effect in biliary tract infections. Jpn J Antibiot 1992;45:557-68.
83. Saito I, Suzuki A, Saiko Y, Yokozawa M, Ono K. Acute nongonococcal epididymitis. Aetiology and levofloxacin therapy. Drugs 1993;45(suppl 3):379.
84. Saito I, Suzuki A, Saiko Y, Yokozawa M, Ono K. Acute nongonococcal epididymitis - pharmacological and therapeutic aspects of levofloxacin. Acta Urol Jpn 1992;38:623-8.
85. Yamashita M, Sawada K, Chokyn H, et al. Prostatic tissue levels of levofloxacin. Chemotherapy 1992;40(suppl 3):203-9.
86. Soyama Y, Mizuhara H, Iwata Y. Fundamental study on levofloxacin in the field of obstetrics and gynecology. Jpn J Antibiot 1992;45:265-9.
87. Ito K, Mikamo H, Izumi K, Tamaya T, Hirose R, Yamada Y. Penetration of levofloxacin into gynecological tissues. Chemotherapy 1992;40(suppl 3):306-10.
88. Takahashi H, Mogi S, Kobayashi M, et al. Assay of skin level and clinical investigation of levofloxacin in the treatment of skin infections. Chemotherapy 1992;40(suppl 3):286-305.
89. Inagaki Y, Nakaya R, Chida T, Hashimoto S. The effect of levofloxacin, an optically active isomer of ofloxacin, on fecal microflora in human volunteers. Jpn J Antibiot 1992;45:241-52.
90. Murata M, Ohnishi K, Irimajiri S, et al. Clinical trial of levofloxacin (DR-3355) and fecal drug concentration and change in the fecal microflora in infectious enteritis. Chemotherapy 1992;40(suppl 3): 170-87.
91. Giamarellou H, Kolokythas E, Petrikkos G, et al. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med 1989;87(suppl 5A):49-51.
92. Nozaki-Renard J, Iino T, Sato Y, et al. Fluoroquinolones protect the human lymphocyte CEM cell line from HIV-1 mediated cytotoxicity. Cell Struct Funct 1990;15:295-9.
93. Pascual A, Garcia I, Perea EJ. Uptake and intracellular activity of an optically active ofloxacin isomer in human neutrophils and tissue culture cells. Antimicrob Agents Chemother 1990;34:277-80.
94. Pascual A, Garcia I, Conejo MC, et al. Fluorometric and high-performance liquid Chromatographic measurement of quinolone uptake by human neutrophils. Eur J Clin Microbiol Infect Dis 1991;10:969-71.
95. Gaja M, Higa F, Yamashiro T, et al. Penetration of levofloxacin, a new quinolone antibacterial agent, into human neutrophils. Chemotherapy 1992;40(suppl 3):64-7.
96. Taira K, Koga H, Kohno S. Accumulation of a newly developed fluoroquinolone, OPC-17116, by human polymorphonuclear leukocytes. Antimicrob Agents Chemother 1993;37:1877-81.
97. Gaitonde MD, Mendes P, House ESA, Lehr K-H. The effects of cimetidine and probenecid on the pharmacokinetics of levofloxacin [abstr]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-29, 1995.
98. Rogge MC, Chien S-C, Wong F, Holland ML. Single-dose pharmacokinetics of levofloxacin: influence of age and gender [abstr]. Presented at the 5th international symposium on new quinolones, Singapore, Malaysia, August 25-27, 1994.
99. Gisclon LG, Curtin CR, Williams RR, et al. The pharmacokinetics of levofloxacin in subjects with renal impairment, and in subjects receiving hemodialysis or continuous ambulatory peritoneal dialysis [abstr]. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996.
100. Chien SC, Chow AT, Williams R, et al. Absence of an effect of levofloxacin on digoxin pharmacokinetics [abstr]. Presented at the annual meeting of the American Academy of Pharmaceutical Scientists, New Brunswick, NJ, June 5-6, 1995.
101. Doose DR, Walker SA, Chien SC, Fowler CA, Nayak RK. Absence of an effect of levofloxacin on cyclosporine pharmacokinetics in healthy adult volunteers [abstr]. Presented at the annual meeting of the American Academy of Pharmaceutical Scientists, New Brunswick, NJ, June 5-6, 1995.
102. Saito A, Oguchi K, Harada Y, et al. Pharmacokinetics of levofloxacin in patients with impaired renal function. Chemotherapy 1992;40(suppl 3):188-95.
103. Aoki N, Usuda Y, Koda Y, et al. Clinical pharmacology and efficacy of levofloxacin in elderly patients. Jpn J Antibiot 1992;45:530-8.
104. Preston SL, Drusano GL, Berman AL, et al. Levofloxacin (L) population pharmacokinetics (PK) and creation of a demographics model for prediction of individual drug clearance in patients with serious community-acquired infection [abstr]. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996.
105. Chien SC, Chow AT, Hendrix C, Williams R, Wong F, Nayak RK. The pharmacokinetics and safety of oral levofloxacin in HIV-infected individuals receiving concomitant zidovudine [abstr]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-29, 1995.
106. Spooner KM, Baird BF, Davey RT, et al. Evaluation of the pharmacokinetics and safety of single and multiple high dose regimens of levofloxacin in HIV seropositive subjects [abstr]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-29, 1995.
107. Blaser J, Stone BB, Groner MC. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987;31:1054-60.
108. Chalkley LJ, Koornhof HJ. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions. Antimicrob Agents Chemother 1985;28:331-42.
109. Dudley MN, Blaser J, Gilbert D, et al. Bactericidal activity of ciprofloxacin against Ps. aeruginosa and other bacteria in an in vitro capillary model. Rev Infect Dis 1988;10:S34-5.
110. Peloquin CA, Cumbo TJ, Nix DE, et al. Intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: impact of plasma concentrations, organism MIC, and clinical condition on bacterial eradication. Arch Intern Med 1989;149:2269-73.
111. Maderas-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor or fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1996;40:627-32.
112. Palmer SM, Rybak MJ. Pharmacodynamics of once-or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrob Agents Chemother 1996;40:701-5.
113. Kang SL, Rybak MJ, McGrath BJ, Kaatz GW, Seo SM. Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrob Agents Chemother 1994;38:2702-9.
114. Preston SL, Drusano GL, Berman AL, et al. Prospective development of pharmacodynamic relationships between measures of levofloxacin exposure and measures of patient outcome [abstr]. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996.
115. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of pseudomonal sepsis. Antimicrob Agents Chemother 1993;37:483-90.
116. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in severely ill patients. Antimicrob Agents Chemother 1993;37:1073-81.
117. th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996.
118. Nichols R, Smith J, Gentry LO, et al. Multicenter, open-label, active-controlled, randomized comparison of levofloxacin QD vs ciprofloxacin BID in 469 adults with mild-to-moderate skin and skin structure infections [abstr]. Clin Infect Dis 1996;23(4):913.
119. Sydnor A, Kopp EJ, Anthony K, Fowler CL. A multicenter noncomparative study to evaluate the safety and efficacy of oral levofloxacin in the treatment of acute sinusitis in adults [abstr]. Presented at a meeting of the American College of Allergy, Asthma, and Immunology, Boston, November 8-13, 1996.
120. th annual meeting of the Infectious Diseases Society of America, New Orleans, September 18-20, 1996.
121. Kahn JB, Reilly-Gauvin K, Demartin EL, et al. Multicenter, open-label, randomized study to compare the safety and efficacy of oral levofloxacin and biaxin in the treatment of acute maxillary sinusitis in adults [abstr]. Clin Infect Dis 1997;25(2):462.
122. th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996.
123. DeAbate CE, Russell M, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1997;42:206-13.
124. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 1997.
125. Kawai T. Clinical efficacy of levofloxacin 200 mg 3 times daily in the treatment of bacterial lower respiratory tract infections. Drugs 1995;49(suppl 2):416-17.
126. Saito A, Ogawa L, Iwata M, et al. Clinical efficacy of levofloxacin in the elderly patients with respiratory tract infections. Drugs 1995; 49(suppl 2):428-9.
127. File TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin verse ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41(9):1965-72.
128. Kawada Y, Murakami S, Aso Y, et al. Studies on the clinical value of levofloxacin in the treatment of genitourinary tract infections. Chemotherapy 1992;40(suppl 3):249-69.
129. Kawada Y, Aso Y, Kamindono S, et al. Comparative study of DR-3355 and ofloxacin in complicated urinary tract infections [abstr]. Presented at the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 29-October 2, 1991.
130. Richard GA, Childs S, Fowler CL, Pitman W, et al. A comparison of levofloxacin and ciprofloxacin for the treatment of complicated urinary tract infections [abstr]. Clin Infect Dis 1996;23(4):914.
131. Klimberg IW, Fowler CL, Cox CE II, King W, Callery-D'Amico S. A comparison of levofloxacin and lomefloxacin for the treatment of complicated urinary tract infections [abstr]. Presented at the 27th annual meeting and exhibition of the American Society of Consultant Pharmacists, Nashville, TN, November 13-16 1996.
132. Richard GA, Klimberg IN, Fowler CL, Callery-D'Amico S. A combined analysis of levofloxacin verse ciprofloxacin or lomefloxacin for the treatment of acute pyelonephritis [abstr]. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996.
133. Kawada Y, Kumamoto Y, Aso Y, et al. Comparative study on levofloxacin and ofloxacin in complicated urinary tract infections. Chemotherapy 1992;40(suppl 3):230-48.
134. Kawada Y, Kumamoto Y, Aso Y, et al. Dose finding study on levofloxacin in complicated urinary tract infections. Chemotherapy 1992;40(suppl 3):210-29.
135. Saito A, Irabu Y, Fukuhura H, et al. Dose finding comparative study on levofloxacin (LVFX) in chronic respiratory tract infection. Chemotherapy 1992;40(suppl 3):75-96.
136. Soejima R, Kawane H, Okimoto N, et al. Comparative study of levofloxacin and ofloxacin in bacterial pneumonia by the double-blind method. Chemotherapy 1992;40(suppl 3):121-46.
137. Soejima R, Kawane H, Okimoto N, et al. Comparative study of levofloxacin and ofloxacin in chronic respiratory tract infections by the double-blind method. Chemotherapy 1992;40(suppl 3):97-120.
138. Saito A, Shigeno Y, Irabu Y, et al. Clinical study on levofloxacin in the field of internal medicine. Chemotherapy 1992;40(suppl 3):147-69.
139. Ortho-McNeil Pharmaceuticals. Levaquin product information reference source. Raritan, NJ;January 1997.
140. Kato M, Furuhama K, Woolley APAH, et al. Twenty-six week oral toxicity of the new quinolone antibacterial agent levofloxacin in rats and cynomolgus monkeys. Arzneimittelforschung 1992;42:367-73.
141. Stahlmann R. Safety profile of the quinolones. J Antimicrob Chemother 1990;26(suppl D):31-44.
142. Todd PA, Faulds D. Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology and therapeutic use. Drugs 1991;42(5):825-76.
143. Davis GH, McKenzie BE. Toxicologic evaluation of ofloxacin. Am J Med 1989;87(suppl 6C):43S-6.
144. Szarfman A, Chen M, Blum MD. More on fluoroquinolone antibiotics and tendon rupture. N Engl J Med 1995;332:193.
145. Huston KA. Achilles tendinitis and tendon rupture due to fluoroquinolone antibiotics. N Engl J Med 1994;331:748.
146. Wagai N. Phototoxic potential of the new quinolone antibacterial agent levofloxacin in mice. Arzneimittelforschung 1992;42:404-5.
147. Radandt JM, Marchbanks CR, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin Infect Dis 1992;14:272-84.
148. Tanaka M, Kurata T, Fujisawa C, et al. Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide. Antimicrob Agents Chemother 1993;37:2173-8.
149. Nix DE, Wilton JH, Schentag JJ, et al. Inhibition of norfloxacin absorption by antacids and sucralfate. Rev Infect Dis 1989;11(suppl 5):S1096-8.
150. Shiba K, Sakai O, Shimada J, Okazaki O, Aoki H, Hakusui H. Effect of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother 1992;36:2270-4.
151. Polk RE, Healy DP, Sahai J, et al. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989;33:1841-4.
152. Liao S, Palmer M, Fowler CL, Nayak RK. Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers. J Clin Pharmacol 1996;36:1072-7.
153. Niki Y, Hashiguchi K, Kimura M, Okimoto N, Soejima R. Quinolone antimicrobial agents and theophylline [letter]. Chest 1992;101:881.
154. Okimoto N, Niki Y, Soejima R. Effect of levofloxacin on serum concentration of theophylline. Chemotherapy 1992;40(suppl 3):68-74.
155. Gisclon LG, Curtin CR, Fowler CL, Nayak RK. Absence of a pharmacokinetic interaction between intravenous theophylline and orally administered levofloxacin [abstr]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-29, 1995.
156. Beckmann J, Elsäßer W, Gundert-Remy U, et al. Enoxacin-a potent inhibitor of theophylline metabolism. Eur J Clin Pharmacol 1987;33:227-30.
157. Höffken G, Lode H, Wiley R, et al. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Rev Infect Dis 1988;10(suppl 1): S138-9.
158. Holland ML, Chow AT, Chien S-C, Goodwin D, Hendrix C, Rogge MC. The pharmacokinetics of oral levofloxacin in HIV-infected individuals with or without concomitant zidovudine [abstr]. Presented at the 5th international symposium on new quinolones, Singapore, Malaysia, August 25-27, 1994.